Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication

被引:87
作者
Addison, WR
Walters, KA
Wong, WWS
Wilson, JS
Madej, D
Jewell, LD
Tyrrell, DLJ
机构
[1] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada
[2] Univ Alberta, Glaxo Wellcome Res Ctr, Edmonton, AB T6G 2S2, Canada
[3] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2R7, Canada
[4] Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada
基金
英国惠康基金;
关键词
D O I
10.1128/JVI.76.12.6356-6363.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Covalently closed circular DNA (cccDNA) is a crucial intermediate in the replication of hepadnaviruses. We inhibited the replication of duck hepatitis B virus in congenitally infected ducks with a combination of lamivudine and a dideoxyguanosine prodrug. Inhibition of viral replication should prevent renewal of the cccDNA pool, and its decay was measured in liver biopsy samples collected over a 5-month period. In three ducks, the cccDNA pools declined exponentially, with half-lives ranging from 35 to 57 days. In two others, the pools declined exponentially for about 70 days but then stabilized at about 6 copies/diploid genome. The selection of drug-resistant virus mutants is an unlikely explanation for this unexpected stabilization of cccDNA levels. Liver sections stained for the cell division marker PCNA showed that animals in which cccDNA loss was continuous had significantly greater numbers of PCNA-positive nuclei than did those animals in which cccDNA levels had plateaued.
引用
收藏
页码:6356 / 6363
页数:8
相关论文
共 32 条
[1]   A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus [J].
Addison, WR ;
Wong, WWS ;
Fischer, KP ;
Tyrrell, DLJ .
ANTIVIRAL RESEARCH, 2000, 48 (01) :27-37
[2]   Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy [J].
Chayama, K ;
Suzuki, Y ;
Kobayashi, M ;
Kobayashi, M ;
Tsubota, A ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1998, 27 (06) :1711-1716
[3]   THE HALF-LIFE OF DUCK HEPATITIS-B VIRUS SUPERCOILED DNA IN CONGENITALLY INFECTED PRIMARY HEPATOCYTE CULTURES [J].
CIVITICO, GM ;
LOCARNINI, SA .
VIROLOGY, 1994, 203 (01) :81-89
[4]   Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA [J].
Dandri, M ;
Burda, MR ;
Will, H ;
Petersen, J .
HEPATOLOGY, 2000, 32 (01) :139-146
[5]   A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].
DIENSTAG, JL ;
PERRILLO, RP ;
SCHIFF, ER ;
BARTHOLOMEW, M ;
VICARY, C ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661
[6]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[7]   Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] in vitro [J].
Fischer, KP ;
Tyrrell, DLJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1957-1960
[8]   Lamivudine resistance in hepatitis B: mechanisms and clinical implications [J].
Fischer, KR ;
Gutfreund, WS ;
Tyrrell, DL .
DRUG RESISTANCE UPDATES, 2001, 4 (02) :118-128
[9]   ALTERATION OF INFECTION PATTERN OF DUCK HEPATITIS-B VIRUS BY IMMUNOMODULATORY DRUGS [J].
FUKUDA, R ;
OKINAGA, S ;
AKAGI, S ;
HIDAKA, M ;
ONO, N ;
FUKUMOTO, S ;
SHIMADA, Y .
JOURNAL OF MEDICAL VIROLOGY, 1988, 26 (04) :387-396
[10]   THE MOLECULAR-BIOLOGY OF THE HEPATITIS-B VIRUSES [J].
GANEM, D ;
VARMUS, HE .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :651-693